(Q37220383)

English

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial

scientific article published on 23 April 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Jean-Charles Soria

2

object named as

J C Soria

0 references

Alexander Eggermont

12

object named as

A M Eggermont

0 references

author name string

J Rodon

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

R Berger

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

G Batist

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

A Tsimberidou

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

C Bresson

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

J J Lee

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

E Rubin

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

A Onn

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

R L Schilsky

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

W H Miller

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

A M Eggermont

12

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

J Mendelsohn

13

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

V Lazar

14

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

R Kurzrock

15

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

publication date

23 April 2015

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

26

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1791-1798

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Integrated molecular portrait of non-small cell lung cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Emerging landscape of oncogenic signatures across human cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

The Cancer Genome Atlas Pan-Cancer analysis project

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Molecular profiling and the reclassification of cancer: divide and conquer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Designing transformative clinical trials in the cancer genome era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Genomic medicine frontier in human solid tumors: prospects and challenges

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Existing and emerging technologies for tumor genomic profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

PIK3CA mutations in advanced cancers: characteristics and outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Comprehensive molecular portraits of human breast tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Comprehensive genomic characterization of squamous cell lung cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Overcoming implementation challenges of personalized cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Translating cancer 'omics' to improved outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Personalized oncology through integrative high-throughput sequencing: a pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

6 September 2017

A cancer trial scandal and its regulatory backlash

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

3 September 2018

Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

3 September 2018

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5006164

3 September 2018

Reimbursement for cancer treatment: coverage of off-label drug indications

1 reference

https://pubmed.ncbi.nlm.nih.gov/25908602

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insurance status and the use of guideline therapy in the treatment of selected cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/25908602

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biology-driven phase II trials: what is the optimal model for molecular selection?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25908602

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

WIN Consortium--challenges and advances

1 reference

https://pubmed.ncbi.nlm.nih.gov/25908602

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer: the road to Amiens

1 reference

https://pubmed.ncbi.nlm.nih.gov/25908602

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDV191

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37220383&oldid=1694901027"